PC-SPES for the treatment of prostate cancer?

Journal of Herbal Pharmacotherapy

Volumn 2, Issue 3, 2002, Pages 73-89

  Chavez, Mary L ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Chinese herbal drug; PC SPES; Prostate cancer

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BAICALEIN; BAICALIN; BICALUTAMIDE; CHRYSANTHEMUM EXTRACT; DIETHYLSTILBESTROL; ESTROGEN DERIVATIVE; FLAVONOID; FLUTAMIDE; GANODERMA LUCIDUM EXTRACT; GLYCYRRHIZA EXTRACT; GONADORELIN AGONIST; GOSERELIN; HERBACEOUS AGENT; INDIRUBIN; ISATIS EXTRACT; KETOCONAZOLE; LEUPRORELIN; NILUTAMIDE; PANAX NOTOGINSENG EXTRACT; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; UNCLASSIFIED DRUG; WOGONIN;

AGED; ANAMNESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CASE REPORT; CHRYSANTHEMUM; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; ERECTILE DYSFUNCTION; GANODERMA; GASTROINTESTINAL SYMPTOM; GINSENG; GLYCYRRHIZA; GYNECOMASTIA; HEADACHE; HEART ATRIUM ARRHYTHMIA; HUMAN; IMPOTENCE; ISATIS; KIDNEY FAILURE; LEG CRAMP; MALE; MEDICINAL PLANT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SABAL; SUPPORT GROUP; SYMPTOMATOLOGY;

EID: 0036342263     PISSN: 15228940     EISSN: None     Source Type: Journal    
DOI: 10.1300/J157v02n03_07     Document Type: Article

References (54)

1. Cancer statistics, 2001
2. Prostate cancer
3. Genitourinary cancers
4. Family history facilitates the early diagnosis of prostate carcinoma
5. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
6. New Gene Finding May Yield Clues to Prostate Cancer Complexity
7. Nutrition and prostate cancer: Evidence or suspicion?
8. Prostate cancer
9. Hormone refractory prostate cancer. Nutrition and prostate cancer
10. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
11. Treatment of prostate cancer: Watchful waiting, radical prostatectomy and cryoablation
12. State-of-the-art prostate cancer treatment and research. A report from The Cancer Institute of New Jersey
13. Maximum androgen blockade in advanced prostate cancer: An overview of the randomized trials
14. Complete androgen blockade for prostate cancer: What went wrong?
15. PC-SPES: Current evidence and remaining questions
16. Chinese herbal mixture PC SPES in treatment of prostate cancer
17. Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer: Single institutional experience
18. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer
19. Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy
20. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: An epidemiological analysis
21. Constituents of compositae plants. 2. Triterpene diols, triols, and their 3-O-fatty acid esters from edible chrysanthemum flower extract and their anti-inflammatory effects
22. Prevention of the development of preneoplastic lesions, aberrant crypt foci, by a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia in male F344 rats
23. The anti-tumor effect of Ganoderma lucidum is medicated by cytokine released from activated macrophages and T lymphocytes
24. Cytotoxicity of Ganoderma lucidum triterpens
25. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against metha-A and LLC tumor cells
26. Effect of glycyrrhetinic acid on DNA damage and unscheduled DNA synthesis induced by benzo(a)pyrene
27. Blockage of glyrrhiza uralensis and chelidonium majus in MNNG induced cancer and mutagenesis
28. Anti-carcinogenic activity of the roots of Panax notoginseng. II
29. Potentiation by Rabdosia rubescens on chemotherapy of advanced esophageal carcinoma
30. Induction of quinone reductase by a methanol extract of Scutellaria baicalensis and its flavonoids in murine Hepa 1c1c7 cells
31. Extract from Serenoa repens suppresses the invasion activity of human urological cancer cells by inhibiting urokinase-type plasminogen activator
32. Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells
33. Clinical and biologic activity of an estrogenic herbal combination (PC SPES) in prostate cancer
34. PC-SPES and prostate cancer
35. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate cell LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
36. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer
37. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC SPES
38. PC-SPES: A unique inhibitor of proliferation of prostate cells in vitro and in vivo
39. Induction of apoptosis and down-regulation of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES
40. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer
41. A phase II study of PC-SPES, an herbal compound, for the treatment of advanced prostate cancer (PCa)
42. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients
43. Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer
44. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer
45. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer
46. Acquired bleeding diathesis in a patient taking PC-SPES
47. Disseminated intravascular coagulation and PC-SPES: A case report and literature review
48. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: Two case reports
49. Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease
50. The use of complementary and alternative medicine in prostate cancer patients
51. UsToo PC-SPES surveys: Review of studies and update of previous survey results
52. A randomized phase II trial of sequential PC-SPES and DES, or DES followed by PC-SPES, in patients with androgen-independent prostate cancer